VanEck Vectors ETFs
Why GNRX? Access Affordable Pharma
GNRX: Fund Profile
Subscribe to email updates
VanEck Vectors™ Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.
30-Day SEC Yield1
Total Net Assets
Number of Holdings
Gross Expense Ratio2
Net Expense Ratio/TER2
Next Distribution Date
Industry may benefit from ongoing push to lower health care costs
The only ETF offering global exposure to generic drug producers
Positioned to take advantage of the expected growth of biosimilars
Index Total Return Ticker
Intraday NAV (IIV)4
Gross Expense Ratio
Fee Waivers andExpense Reimbursement
*Returns less than one year are not annualized.
The table presents past performance which is no guarantee of future results and which may be lower or higher than current performance. Returns reflect temporary contractual fee waivers and/or expense reimbursements. Had the ETF incurred all expenses and fees, investment returns would have been reduced. Investment returns and ETF share values will fluctuate so that investors' shares, when redeemed, may be worth more or less than their original cost. ETF returns assume that dividends and capital gains distributions have been reinvested in the Fund at NAV.
The "Net Asset Value" (NAV) of a VanEck Vectors Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell shares at NAV.